CAMBRIDGE, Mass. and MILL VALLEY, Calif., Oct. 14, 2020 /PRNewswire/ — Today, MIT Sloan Management Review announced the 2020 Culture Champions, as determined by the Culture 500, a groundbreaking study that scientifically compares the corporate cultures of more than 500 of the largest companies driving the U.S. economy.
The Culture Champions list comes out of the Culture 500, a large-scale, interactive research study conducted by researchers at the MIT Sloan School of Management. Studying over 1.4 million Glassdoor reviews from more than 500 of the largest employers in the United States, the Culture 500 is notable for its large scale — it is one of the largest studies of corporate culture ever conducted — and use of groundbreaking AI technology developed at MIT to make sense of over a million employee reviews.
The standout organizations in the study, the 21 Culture Champions were recognized because their employees
Preliminary results from two independent, phase II clinical trials investigating a new PD-1 (programmed cell death protein 1)-based immune therapy for metastatic cervical cancer suggest potential new treatment options for a disease that currently has limited effective options and disproportionately impacts younger women.
David O’Malley, MD, of The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), presented the preliminary study results at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 on Sept. 18. O’Malley was the lead presenter for both trials, which were sponsored by Agenus Inc.
Each study involved more than 150 patients with recurrent or metastatic cervical cancer from cancer treatment centers across the United States and Europe. All patients were previously treated with platinum-based chemotherapy as a first-line therapy. The two independent but consecutive phase II trials tested a new immune-based agent
ARLINGTON, Va., Oct. 5, 2020 /PRNewswire/ — The Board of Directors of the Potomac Institute for Policy Studies is pleased to announce the promotion of Dr. Jennifer Buss to Chief Executive Officer, and selection of General Al Gray as the new Chairman of the Board. Dr. Buss will immediately assume all duties and responsibilities that accompany the CEO position at the Institute. She was also named a member of the Board of Directors.
“I am incredibly humbled and honored to lead the Institute. I’ve been invested in its mission since I arrived,” Dr. Buss said. “I am committed to progressing the Institute and its contributions to policy in ever-changing science and technology.”
Dr. Buss replaces Mike Swetnam, who passed away in September. “Mike challenged and inspired me every day. It is because of his mentoring, and the leadership of General Al Gray, that I am ready for this new opportunity.”
Two and a half years ago, MIT entered into a research agreement with startup company Commonwealth Fusion Systems to develop a next-generation fusion research experiment, called SPARC, as a precursor to a practical, emissions-free power plant.
Now, after many months of intensive research and engineering work, the researchers charged with defining and refining the physics behind the ambitious reactor design have published a series of papers summarizing the progress they have made and outlining the key research questions SPARC will enable.
Overall, says Martin Greenwald, deputy director of MIT’s Plasma Science and Fusion Center and one of the project’s lead scientists, the work is progressing smoothly and on track. This series of papers provides a high level of confidence in the plasma physics and the performance predictions for SPARC, he says. No unexpected impediments or surprises have shown up, and the remaining challenges appear to be manageable. This sets a
IP2 Accelerates CCS-enabled 4D-Proteomics™ with GPU-based Scalable Search Engine
IP2 Adds ‘Run & Done’ Real-Time Capabilities to timsTOF® Proteomics Systems
Bruker Corporation (Nasdaq: BRKR) announces the recent acquisition of the Integrated Proteomics Pipeline (IP2) search engine and proteomics workflow software platform. IP2 was developed by Integrated Proteomics Applications Inc, a company founded by leading proteomics researcher Professor John Yates III, together with Drs. Robin Park and Tao Xu. Financial details of the transaction were not disclosed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200930005135/en/
Prof. John Yates III, The Scripps Research Institute (Photo: Business Wire)
This acquisition further enhances Bruker’s solutions for CCS-enabled 4D-Proteomics™ by adding fast, scalable and GPU-based search engine capabilities for faster data processing and full utilization of molecular collision cross sections (CCS). Benefits include greater data completeness and higher confidence in protein and PTM identification and quantification in unbiased ‘shot-gun’ proteomics. Bruker’s
The anxiety, stress and worry brought on by COVID-19 is not limited to daytime hours. The pandemic is affecting our dreams as well, infusing more anxiety and negative emotions into dreams and spurring dreams about the virus itself, particularly among women, according to research published by the American Psychological Association.
In a special section in the journal Dreaming, researchers reported on the results of four studies from around the world about people’s dreams during the pandemic. Previous research has suggested that our dreams often reflect what’s happening in our waking lives and that other crises — including war, natural disasters and terrorist attacks — have led to an increase in anxious dreams. The four studies in this special section found that the same is true of COVID-19.
“All of these studies support the continuity hypothesis of dreaming: That dreams are consistent with our waking concerns rather than being some